Browsing Tag
GSK plc
18 posts
GSK wins approval in China for Nucala in eosinophilic COPD, expanding respiratory biologics reach
Find out how GSK’s Nucala just became the first biologic approved for eosinophilic COPD in China—and what it means for the future of respiratory care.
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
GSK’s Shingrix wins China approval for adults 18+ — Can this vaccine expansion reignite its global growth story?
Find out how GSK’s Shingrix approval in China for adults aged 18+ could reshape its vaccine business and investor confidence. #GSK #Shingrix
GSK to acquire efimosfermin from Boston Pharmaceuticals for $2bn to bolster liver disease pipeline
GSK acquires Phase III-ready efimosfermin from Boston Pharmaceuticals for $2B, expanding its liver disease pipeline with a fibrosis-reversing specialty drug.
GSK Q1 2025 earnings: Specialty medicines power growth as pipeline builds investor confidence
GSK's Q1 2025 earnings beat forecasts on strong Specialty Medicines growth and pipeline strength—read full results, investor sentiment, and stock outlook.
GSK secures FDA breakthrough therapy designation for GSK5764227 in lung cancer treatment
GSK plc (LSE/NYSE: GSK) has announced a significant milestone in its oncology program, with the US Food and…
GSK secures expanded approval for Jemperli from FDA: A major advancement in endometrial cancer treatment
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab)…
GSK announces significant survival results for Jemperli in endometrial cancer trial
In a significant development for patients with primary advanced or recurrent endometrial cancer, GSK plc (LSE/NYSE: GSK) has…